Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
KalVista Pharmaceuticals, Inc. (KALV) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 8-K Quarterly results
07/07/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "KalVista Pharmaceuticals Inc. Condensed Consolidated Balance Sheets April 30, April 30, 2023 2022 Assets Current assets: Cash and cash equivalents $56,238 $30,732 Marketable securities 93,137 135,470 Research and development tax credit receivable 16,568 14,098 Prepaid expenses and other current assets 6,383 13,347 Total current assets 172,326 193,647 Property and equipment, net 2,948 2,178 Right of use assets 7,822 7,862 Other assets 106 193 Total assets $183,202 $203,880 Liabilities and stockholders' equity Current liabilities: Accounts payable $4,817 $3,638 Accrued expenses 9,128 6,961 Lease liability - current portion 1,087 977 Total current liabilities 15,032 11,576 Long-term liabilities: Lease liability - net of current portion 7,145 7,211 Total long-term liabilities 7,145 7,211stock..."
03/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "KalVista Pharmaceuticals Inc. Condensed Consolidated Balance Sheets January 31, April 30, 2023 2022 Assets Current assets: Cash and cash equivalents $ 85,049 $ 30,732 Marketable securities 86,636 135,470 Research and development tax credit receivable 11,892 14,098 Prepaid expenses and other current assets 8,556 13,347 Total current assets 192,133 193,647 Property and equipment, net 3,037 2,178 Right of use assets 8,101 7,862 Other assets 197 193 Total assets $ 203,468 $ 203,880 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,698 $ 3,638 Accrued expenses 8,851 6,961 Lease liability - current portion 1,057 977 Total current liabilities 11,606 11,576 Long-term liabilities: Lease liability - net of current portion 7,421 7,211 Total long-term liabilities 7,421 7,..."
01/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice President, Corporate Communications 705-0254 [email protected]"
12/27/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Pre-Funded Warrant",
"Opinion of Fenwick & West LLP",
"Subscription Agreement, by and among KalVista Pharmaceuticals, Inc. and the purchasers identified on the signature pages thereto"
12/08/2022 8-K Quarterly results
10/17/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice President, Corporate Communications 705-0254 [email protected]"
09/08/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "KalVista Pharmaceuticals Reports First Fiscal Quarter Results - KVD824 Phase 2 Clinical Trial Reaches 50% Enrollment Milestone - - Open Label Extension Study Initiated for Sebetralstat - Cambridge, MA and Salisbury, England, September 8, 2022 – KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2022."
07/07/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
03/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "KalVista Pharmaceuticals Inc. Condensed Consolidated Balance Sheets January 31, April 30, 2022 2021 Assets Current assets: Cash and cash equivalents $ 45,577 $ 50,592 Marketable securities 149,212 198,337 Research and development tax credit receivable 11,287 10,418 Prepaid expenses and other current assets 8,388 4,917 Total current assets 214,464 264,264 Property and equipment, net 2,215 1,791 Right of use assets 8,180 5,758 Other assets 193 200 Total assets $ 225,052 $ 272,013 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,185 $ 1,981 Accrued expenses 6,450 6,930 Lease liability - current portion 1,014 863 Total current liabilities 9,649 9,774 Long-term liabilities: Lease liability - net of current portion 7,467 5,046 Total long-term liabilities 7,467 5,04..."
03/07/2022 8-K Quarterly results
12/09/2021 8-K Quarterly results
10/04/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
09/15/2021 8-K Quarterly results
09/09/2021 8-K Quarterly results
07/13/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results – FDA End-of-Phase 2 Meeting on KVD900 Oral HAE Phase 3 Program Scheduled for Late Q3 2021 –"
06/30/2021 8-K Quarterly results
06/07/2021 8-K Quarterly results
03/19/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
01/27/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
12/18/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/10/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "KalVista Pharmaceuticals Reports Second Fiscal Quarter Results – KVD900 Phase 2 Clinical Trial Patient Treatment Completed; Data Expected Q1 2021 –"
12/01/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
11/16/2020 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 16, 2020 KALVISTA PHARMACEUTICALS, INC. Delaware 001-36830 20-0915291 55 Cambridge Parkway Suite 901E Cambridge, Massachusetts 02142 999-0075 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to R..."
10/02/2020 8-K Quarterly results
09/14/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "KalVista Pharmaceuticals Reports First Fiscal Quarter Results – KVD900 On-Demand Data Expected Q4 2020 –"
07/01/2020 8-K Quarterly results
06/11/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Bylaws Amendment"
03/10/2020 8-K Quarterly results
12/03/2019 8-K Quarterly results
Docs: "”"
10/03/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy